Investigational drug · Phase 3
000 MG01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic.
Phase 3Last checked: Nov 19, 2026Latest source record: May 13, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
0
Any phase or sponsor naming "000 MG01"
First trial start
2021
May 31, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "000 MG01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rhinitis, Allergic
- Rhinoconjunctivitis
- Asthma, Allergic
Approved drugs for the same conditions: Asthma · Respiratory · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "000 MG01" as an intervention, largest first.
- Efficacy and Safety Evaluation of the Treatment of Allergy Against Cupressaceae and Grasses.
NCT04898283 · Phase 3 · Recruiting · Inmunotek S.L. · 180 participants · primary completion Oct 2026
- Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
NCT04891237 · Phase 3 · Recruiting · Inmunotek S.L. · 180 participants · primary completion Jan 2026
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Rhinitis, Allergic
- 000 MM09Phase 32 trials
Inmunotek S.L. · Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.